HCW Biologics Inc is trading 6.7% down at $1.67 in pre-market, extending weakness following its Q1 update and ongoing Nasdaq minimum bid-price compliance concerns.
- The stock is facing downward pressure from potential dilution related to a recently priced private placement.
- Market sentiment remains cautious as investors weigh an unusual Q1 EPS beat for the pre-revenue biotech against persistent regulatory listing requirements.